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responses in vivo, because mannitol inhib-
its NaCl transport in the loop of Henle and 
the MD cell.6 It is harder to understand the 
major negative impact of isotonic glucose 
and amino acids (5 and 5 mM, respec-
tively) in late proximal perfusion, which 
inhibited 60% of the TGF response in vivo.8 
This effect was associated with a major 
reduction in loop of Henle chloride trans-
port. Th ese molecules may express refl ec-
tion coeffi  cients of 1.0 for the MD, higher 
than for the NaCl, and are not actively 
transported by the MD cell. Luminal NaCl 
concentrations and osmolality near the 
MD were not diff erent. Th ese results may 
relate to the fi ndings that hyperglycemia 
and experimental diabetes are conditions 
associated with modest but significant 
reductions in TGF activity. Studies are 
required to quantify and fully characterize 
the aff erent arteriolar and TGF responses 
to specifi c changes in (1) luminal NaCl, 
(2) luminal osmolality, and (3) the identity 
of the specifi c solutes contributing to the 
luminal osmotic pressure and changes in 
MD cell volume. 
Komlosi and co-workers1 have now 
provided valuable boundary conditions 
on the eff ects of increased luminal NaCl 
and luminal osmolality on MD cell vol-
ume. Further studies are required on the 
specifi c role of decreased MD cell vol-
ume in the magnitude, direction, and 
character of the TGF sensor. Combined 
in vivo and in vitro assessments within 
the relevant range of changes in lumi-
nal NaCl and osmolality will help us to 
understand the operation of this com-
plex and important regulatory system. 
Th e article by Komlosi and co-workers1 
represents an excellent fi rst step in this 
direction. Th erefore, their study is not 
basic and parochial in nature. It is basic 
and highly relevant to physiology and 
even clinical nephrology if one under-
stands the issues. 
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Revascularization in 
atherosclerotic renovascular 
disease: Problems beyond the 
obstruction
AR Chade1
The main goal in the treatment of obstructive atherosclerotic 
renovascular disease (ARVD) is to preserve or recover renal function. 
The ARVD kidney continues to deteriorate in 20–40% of cases despite 
restoration of blood flow. Holden et al. report that renal function 
stabilized or improved in up to 97% of patients with the use of a distal 
embolic protection device.
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The patient population with end-stage 
renal disease has been growing at a rate of 
8%–14% per year for the past two decades.1 
In almost one-third of those cases, athero-
sclerotic renovascular disease (ARVD) has 
been the cause of end-stage renal disease. 
Atherosclerotic lesions account for more 
than 90% of cases of renal artery lesions 
and are the cause of end-stage renal dis-
ease in up to 27% of patients over 45 years 
of age at the start of dialysis. 
The main goal in the treatment of 
obstructive ARVD is to recover or pre-
serve renal function. Underlining this 
concept is the notion that ARVD is a 
progressive disorder. Major advances 
in revascularization techniques have 
emerged during the past 20 years. Per-
cutaneous transluminal renal angioplasty 
(PTRA) and stenting have become the 
common treatments for patients with 
clinically signifi cant renal artery stenosis 
and reversible renal disease. PTRA has a 
high success rate, long-term patency, and 
a low complication rate. Nevertheless, 
these treatments oft en fail to improve 
blood pressure or renal function despite 
successful renal revascularization. Post-
PTRA deterioration of renal function 
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may occur in 20–40% of patients, which 
limits the immediate benefi ts of the tech-
nique.2 Indeed, the complex nature of 
ARVD, marked by deterioration of renal 
function and increasing morbidity and 
mortality of cardiovascular disease, is 
the impetus for ongoing clinical studies 
seeking adequate therapy (for example, 
the Cardiovascular Outcomes in Renal 
Atherosclerotic Lesions (CORAL), 
Regional Angiogenesis with Vascular 
Endothelial Growth Factor (RAVE), and 
Prospective Randomized Study Com-
paring Renal Artery Stenting (RESIST) 
trials). 
Angioplasty and stenting of the renal 
atherosclerotic lesion constitute the 
most emboligenic part of the procedure 
as demonstrated both in vivo3,4 and ex 
vivo.5 Tsao et al.6 treated significant 
ARVD with delicate PTRA plus stenting 
without distal protection. Th is approach 
requires minimal device manipulation 
in both the pre-dilatation and the stent-
ing stages to minimize potential injuries 
to dilated vessels as well as vessels distal 
to the obstruction due to atheroembo-
lism. In the study, more than 90% of the 
patients stabilized or improved their 
renal function (results similar to those 
reported by Holden et al.3 in this issue) 
in the absence of any clinical signs or 
symptoms of atheroembolism. PTRA 
plus stenting, which showed major 
improvements in renal function, may 
off er an alternative treatment for ARVD, 
considering the challenge of using a 
distal protection device relative to its 
size or to renal artery anatomy. Never-
theless, this approach may not exclude 
the possibility of renal atheroembolism. 
Cholesterol emboli are thought to occur 
in approximately 50% of percutaneous 
interventions, most of them clinically 
silent.7 Furthermore, atheroemboli may 
not only occlude smaller vessels distal to 
the stenosis but may produce local vas-
cular infl ammation and cause substan-
tial damage to the renal parenchyma. It 
is possible that atherogenic lipoproteins 
(for example, oxidized low-density lipo-
protein) present in those debris as well 
as circulating cytokines may induce 
endothelial- and epithelial-cell dysfunc-
tion and vascular damage distal to the 
stenosis and infi ltrate the mesangium 
and blood vessels,8 subsequently induc-
ing secretion of growth factors that lead 
to glomerular and vascular remodeling 
and proliferation of extracellular matrix. 
It is worth noting that PTRA plus stent-
ing is a delicate procedure that demands 
expertise by the operator, which may 
restrict its application.
Holden et al.3 (this issue) address the 
potential problem of PTRA-induced 
embolisms in ARVD by reporting the 
results of a prospective study performed 
in patients with ARVD and blunted renal 
function (glomerular fi ltration rate below 
50 ml per minute per 1.73 m2). They 
evaluated the impact on renal func-
tion using a dual therapeutic approach: 
aggressive balloon dilatation and stent-
ing in combination with a distal embolic 
protection device. Preliminary results 
suggest the feasibility and safety of using 
distal protection devices during PTRA 
and stenting to protect the distal renal 
parenchyma against atheroembolism 
and renal-function deterioration.4,9 On 
the other hand, limitations on the use of 
these devices include the characteristics 
of the atherosclerotic lesions (for exam-
ple, tortuosity), anatomic variants of the 
renal arteries (for example, early branch-
ing), and reduced maneuverability of 
integrated fi lter-guidewire systems.10 
Th e aggressive PTRA technique per-
formed by Holden et al.3 (stent dilated 
up to 7 mm) may have improved kidney 
function if done without distal protec-
tion. Atheroembolic renal failure is one 
of the most common complications of 
PTRA, and the use of intrarenal distal 
protection devices may limit this risk. 
Th erefore, the absence of a control group 
treated without embolic protection rep-
resents a limitation of the study.3 Indeed, 
the outcome of the ischemic kidney in 
ARVD is probably determined not only 
by narrowing of the large arteries but 
also by the prevention, or potential for 
reversibility of intrarenal small-vessel 
compromise. Atheroembolism to distal 
renal beds is more frequent when PTRA 
is performed on long critical lesions with 
a large atheroma load. Notably, Holden 
et al.3 found that macroscopic embolic 
material was present in 60% of the fi l-
ters, and that renal function stabilized or 
improved in more than 90% of patients, 
an outcome that was more evident when 
baseline renal insufficiency was mild 
and recent. Furthermore, the study also 
showed a strikingly low rate of re-steno-
sis (8% of the patients) as compared with 
that found in the literature (15%–20%); 
this probably represents an additional 
benefi t of this dual approach. 
Although these results seem promising, 
unresolved issues remain regarding the 
responses of the ARVD kidney to revas-
cularization that are probably responsible 
for the 20%–40% of patients whose renal 
function continues to deteriorate (Figure 
1). It is possible that part of the problem 
may be due to damage of the renal paren-
chyma, which can progress as ARVD 
evolves. Th e mixed responses to revascu-
larization in ARVD are possibly related 
to existent and progressive renal damage 
distal to the stenosis, or as a consequence 
of intervention in up to 20% of cases. 
Deterioration of renal function in ARVD 
aft er intervention may not only represent 
an acute complication but also disclose 
deleterious mechanisms that progressively 
harm the ARVD kidney during the evolu-
tion of atherosclerosis. Th e consequences 
of this problem may be unmasked aft er 
an additional sudden insult. Th erefore, 
Figure 1 | Distal protection devices may improve outcomes in a sub-population of patients 
in whom renal function fails to improve because of atheroembolism. PTRA, percutaneous 
transluminal renal angioplasty; ARVD, atherosclerotic renovascular disease.
832   Kidney International (2006) 70
commentar y
minimizing the risk of potential compli-
cations such as atheroembolism should be 
considered in the treatment of the sten-
otic kidney. Th erapeutic strategies such as 
those described by Holden et al.3 give us 
hope for rescuing the ischemic kidney and 
may bring us one step closer to defi ning an 
adequate therapeutic strategy to halt the 
progression of renal damage in patients 
with ARVD.
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